Current Science

Open Access Open Access  Restricted Access Subscription Access

The Dnazyme Anti-insulin-like Growth Factor-IIP3 Inhibited Tumour Growth in a Mouse Model of Human Hepatocarcinoma


Affiliations
1 Medical Department, Beihua University, Jilin 132001, China
2 Jilin Central General Hospital, Jilin 132001, China
 

Insulin-like growth factor II promoter 3 (IGF-IIP3) is the most active promoter in live cancer cells. In this study, the anti-tumour growth effects of DRz1 were measured in a model of hepatoma-bearing mice. DRz1 significantly inhibited IGF-IIP3 expression and tumour growth in vivo. Compared to the sham-treated control group, DRz1 treatment attenuated the tumour volume and weight after 14 days of treatment. DRz1 could significantly inhibit the expression of IGF-IIP3, could inhibit the associated tumour-promoting proteins and could retard the growth of hepatocarcinoma tumours in vivo. These findings provide novel evidence for the anti-tumour effects of DRz1 in vivo.

Keywords

Anti-Tumour Growth, Bearing Mouse Model, Hepatocellular Carcinoma, IGF-IIP3-DRz1.
User
Notifications
Font Size


  • The Dnazyme Anti-insulin-like Growth Factor-IIP3 Inhibited Tumour Growth in a Mouse Model of Human Hepatocarcinoma

Abstract Views: 397  |  PDF Views: 143

Authors

Min Zhang
Medical Department, Beihua University, Jilin 132001, China
Chun-Li Mei
Medical Department, Beihua University, Jilin 132001, China
Ji-Dong Liu
Jilin Central General Hospital, Jilin 132001, China

Abstract


Insulin-like growth factor II promoter 3 (IGF-IIP3) is the most active promoter in live cancer cells. In this study, the anti-tumour growth effects of DRz1 were measured in a model of hepatoma-bearing mice. DRz1 significantly inhibited IGF-IIP3 expression and tumour growth in vivo. Compared to the sham-treated control group, DRz1 treatment attenuated the tumour volume and weight after 14 days of treatment. DRz1 could significantly inhibit the expression of IGF-IIP3, could inhibit the associated tumour-promoting proteins and could retard the growth of hepatocarcinoma tumours in vivo. These findings provide novel evidence for the anti-tumour effects of DRz1 in vivo.

Keywords


Anti-Tumour Growth, Bearing Mouse Model, Hepatocellular Carcinoma, IGF-IIP3-DRz1.

References





DOI: https://doi.org/10.18520/cs%2Fv116%2Fi12%2F2072-2077